ProPSA, un nuevo biomarcador para la detección y el manejo del cáncer de próstata

The description of new PSA isoforms associated with prostate cancer, such as proPSA, has expanded the available tools for the detection of this tumor. Since the marketing of an assay for the measurement of [-2] proPSA, one of the fractions of proPSA, we have positive data on the use of the percentage of [-2] proPSA in relation to free PSA (%[-2] proPSA) and the prostate health index (phi), which measures [-2] proPSA, total PSA and free PSA together. The available results suggest that the use of these tests would lead to a reduction in the number of negative biopsies compared with the percentage of free PSA. On other hand, both %[-2] proPSA and phi are related to particularly aggressive tumors, so they could be useful to select patients for active surveillance, and to decide which patients must be treated.